Significados de advanced gist en inglés

This phase II study evaluated masitinib as a first-line treatment of advanced GIST.

ET-743 at this dose and schedule is not an effective treatment for advanced GIST.

Results: Between May 2002 and April 2004, 182 patients with advanced GIST were enrolled.

The treatment was granted 'Fast Track' status in June to treat patients with advanced GIST who have received certain prior treatment.

Conclusion: Patients with advanced GISTs exhibiting stable disease or limited progression on kinase inhibitor therapy have prolonged overall survival after debulking procedures.

In patients with advanced GIST, imatinib should be given until progression, and then, other tyrosine kinase inhibitors targeting KIT should be used.

Methods: In a patient with advanced GIST undergoing imatinib therapy, an isolated progressing peritoneal mass was excised, along with 2 still-responding lesions.

Methods: We evaluated outcomes in a single institution series of 69 consecutive patients who underwent surgery for advanced GISTs while receiving kinase inhibitors.

Conclusions: Masitinib appears to be effective as a first-line treatment of advanced GIST with comparable results to imatinib in terms of safety and response.

Conclusion: Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity

To assess the role of surgery in multimodality management of GISTs, we studied postoperative outcomes in patients treated with targeted kinase inhibitors for advanced GIST.